Inhibiting cyclin activation, a potential drug target, demonstrates neuroprotective and anti-apoptotic effects in experimental models, suggesting the potential of the application of E2F1 in PD treatment (Verdaguer et al., 2007; Folch et al., 2012). Here, E2F1 is linked to Parkinson disease.